Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
- None.
- None.
Insights
The completion of enrollment and dosing in a Phase 1 clinical trial by Vaxart for an oral bivalent norovirus vaccine candidate represents a significant milestone in the development of preventive healthcare measures. The target demographic, lactating mothers, could potentially be a key demographic in the transmission of immunity to their offspring. The anticipation of topline data by the end of 2024 provides a tangible timeline for stakeholders to monitor progress.
From a medical research perspective, the lack of an approved vaccine for norovirus, coupled with the high incidence and economic impact, underscores the potential market demand for Vaxart's vaccine candidate. The annual disease burden in the U.S. alone, quantified at $10.6 billion, indicates a significant financial incentive for the development and successful commercialization of a vaccine.
Examining the economic implications, the norovirus imposes a considerable economic burden due to healthcare costs and lost productivity, with an estimated annual impact of $10.6 billion in the U.S. alone. The development of an effective vaccine could result in substantial cost savings. The direct costs associated with healthcare and indirect costs due to missed workdays, approximately 2.2 days on average per affected family, are critical factors in the cost-benefit analysis of vaccine development.
Furthermore, the global prevalence of norovirus and its designation as the leading cause of pediatric gastroenteritis in settings where the rotavirus vaccine is adopted suggest a broad international market potential. The vaccine's success could lead to reduced morbidity and mortality, particularly in the developing world where the impact is more pronounced.
In the pharmaceutical industry, the progression of a vaccine candidate through clinical trials is a key driver of investor interest. Vaxart's announcement not only marks a critical step in the vaccine's development but also serves as a value proposition to potential investors and partners. The data from this trial will be crucial in determining the safety and immunogenic potential of the vaccine.
Given that norovirus affects approximately 21 million people annually in the U.S., with a notable percentage of children under 5, the vaccine's market potential is substantial. Should the topline data prove positive, Vaxart could position itself as a pioneer in the norovirus vaccine market. However, the long development timelines and the risks inherent in clinical trials must be accounted for in any investment or strategic business decision.
On track to report topline data by the end of 2024
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed enrollment and dosing in the Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate focused on lactating mothers.
“This is an important step forward as we drive toward a vaccine candidate that may make it possible for mothers to protect their children against this highly contagious – and potentially lethal -- virus. We look forward to announcing topline data from this study by the end of 2024,” said Dr. James F. Cummings, Vaxart’s Chief Medical Officer. “We are very proud of our clinical team for completing enrollment of this trial within our planned timeline.”
There is no approved vaccine against norovirus, which sickens approximately 21 million people in the United States each year, and
Globally, norovirus has become the leading cause of pediatric gastroenteritis in health care settings in countries that have adopted a rotavirus vaccine program.1 Pediatric deaths in the United States due to norovirus are rare, but they are much more common in the developing world.
About the VXA-NVV-108 Clinical Trial
The Phase 1, multicenter, randomized, double-blind, placebo-controlled single dose, dose-ranging study is designed to evaluate the safety, tolerability, and immunogenicity of orally administered bivalent GI.1/GII.4 norovirus vaccine in healthy lactating females of at least 18 years of age. The study enrolled 76 subjects at five sites in South Africa. Subjects are randomized into high- or low-dose vaccine (N=30 for each arm) or placebo (N=16). The primary endpoints are:
- Frequency, duration and severity of solicited symptoms of reactogenicity (local and systemic) for one week following study drug dose;
- Frequency, duration and severity of unsolicited treatment-emergent adverse events (TEAEs), serious AEs (SAEs), adverse events of special interest (AESIs) and new onset of chronic illness (NOCIs) through the active period (four weeks post dose);
- Serum VP1-specific (GI.1 and GII.4) IgA on Day 1 (baseline), Day 8 and Day 29 (four weeks post last dose);
- Breastmilk VP1-specific (GI.1 and GII.4) IgA on Day 1 (baseline), Day 8 and Day 29 (four weeks post last dose).
Further information, including information about study funding, can be found in the Company’s press release of December 1, 2022, as well as the Company’s latest quarterly filing.
1 Shah and Hall, Infect Dis Clin North Am. 2018 Mar; 32(1): 103-118.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart's strategy, prospects, plans and objectives, results from preclinical and clinical trials and the timing of such results, commercialization agreements and licenses, and beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as "should," "believe," "could," "potential," "will," "expected," “anticipate,” "plan," and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart's ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart's expectations regarding clinical results and trial data, and the timing of receiving and reporting such clinical results and trial data; and Vaxart's expectations with respect to the effectiveness of its product candidates. Vaxart may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement, and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates, and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart's product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart's product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart's or its partners' control; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Vaxart may not be able to obtain, maintain, and enforce necessary patent and other intellectual property protection; that Vaxart's capital resources may be inadequate; Vaxart's ability to resolve pending legal matters; Vaxart's ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the "Risk Factors" sections of Vaxart's Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.
Contacts
Vaxart Media Relations:
Mark Herr
Vaxart, Inc.
mherr@vaxart.com
(203) 517-8957
Investor Relations:
Andrew Blazier
FINN Partners
IR@vaxart.com
(646) 871-8486
FAQ
What is the latest update from Vaxart, Inc. (VXRT)?
How many people are affected by norovirus in the United States annually?
What is the annual disease burden from norovirus in the U.S.?
